Abstract
HCV infection is usually diagnosed by means of an enzyme immune assay for the detection of antibody against HCV. The window period between infection and seroconversion remains a dramatic problem in the transfusional and diagnostic setting. In this chapter, we report (i) procedures for assays using two different approaches designed to reduce the window period and (ii) performance in terms of specificity and sensitivity in the detection of both antibody and antigen, and we compare their efficacy with that of commercial assays.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barrera, J. M., Francis, B., Ercilla, G., Nelles, M., Archord, D., Darner, J., et al. (1995) Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 68, 15–18.
Brooks, G. F., Butel, J. S., and Morse S. A. (2001) Jawetz, Melnick and Adelberg’s Medical Microbiology, 22nd ed., Lange Medical Books, New York, pp. 406–410.
Busch, M. P., and Kleinman, S. H. (2000) Committee report: nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Transfusion 40, 143–159.
Food and Drug Administration (2002) Guidance for industry: use of nucleic acid tests on pooled and individual samples from blood donors to adequately and appropriately reduce the risk of transmission of HIV-1 and HCV. Federal Register 67, 17077.
Velati, C., Baruffi, L., Romanò, L., Fomiatti, L., Carreri, V., and Zanetti A. (2003) Introduction of NAT method of screening blood donors in Italy: reports of the two years of experience and a re-evaluation of residual risk. Blood Transfus. 4, 368–378
Anonymous (2002) Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. Vox Sang. 82, 87–111.
European Agency for the Evaluation of Medicinal Products (2001) Committee for proprietary medicinal products. Note for guidance on plasma0deried medicinal products. EMEA/CPMP/BWP 269/95 rev.3 London, 25 January 2001.
Courouce, A. M., Le Marrec, N., Bouchardeau, F., Razer, M., Maniez, W. P., Laperche S., et al. (2000) Efficacy of HCV core antigen detection during preseroconversion period. Transfusion 40, 1198–1202.
Icardi, G., Ansaldi, F., Bruzzone, B. M., Durando, P., Lee, S., De Luigi, C., et al. (2001) Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J. Clin. Microbiol. 39, 3110–3114.
Gaudy. C., Thevenas, C., Tichet, J., Mariotte, N., Goudeau, A., and Dubois, F. (2005) Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical check-up. J. Clin. Microbiol. 43, 1722–1726.
Pivert, A., Payan, C., Morand, P., Fafi-Kremer, S., Deshayes, J., Carrat, F., et al. (2006) Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin. J. Clin. Microbiol. 44, 417–422.
Shah, D. O., Chang, C. D., Jiang, L. X., Cheng, K. Y., Muerhoff, A., Gutierrez, R. A., et al. (2003) Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyser. Transfusion 43, 1067–1074.
Laperche, S., La Marrec, N., Girault, A., Bouchardeau, F., Servant-Dalmas, A., Maniez-Montreuil, M., et al. (2005) Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J. Clin. Microbiol. 43, 3877–3883.
Laperche, S., Elghouzzi, M. H., Pascal, M., Asso-Bonnet, M., Le Marrec, N., Girault, A., et al. (2005) Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 45, 1965–1972.
Ansaldi, F., Bruzzone, B., Testino, G., Bassetti M., Gasparini R., Crovari P., et al. (2006) Combination hepatitis C antigen and antibody assay as a new tool for early diagnosis of infection. J. Viral Hepat. 13, 5–10.
Schnuriger, A., Dominguez, S., Valantin,M. A., Tubiana, R., Duvier, C., Ghosn, J., et al. (2006) Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high risk individuals. J. Clin. Microbiol. 44, 1561–1563.
Castillo, I., Pardo, M., Bartholomé, J., Ortiz-Movilla, N., de Lucas, S., Salas, C., et al. (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver function tests is unknown. J. Infect. Dis. 189, 7–14.
Quiroga, J. A., Castillo, I., Pardo, M., Rodriguez-Inigo, E., and Careno, V. (2006) Combined hepatitis antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult infection. J. Clin. Microbio. 44, 4559–4560.
Nubling, C. M., Unger, G., Chudy, M., Raia, S., and Lower, J. (2002) Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 42, 1037–1045.
Maynard, M., Pradat, P., Berthillon, P.,Picchio, G., Voirin, N., Martinot, M., et al. (2003) Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients response to therapy. J Viral Hepat. 10, 318–323.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ansaldi, F., Icardi, G. (2009). Simultaneous Detection of Anti-HCV Antibody and HCV Core Antigen. In: Tang, H. (eds) Hepatitis C. Methods in Molecular Biology™, vol 510. Humana Press. https://doi.org/10.1007/978-1-59745-394-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-59745-394-3_2
Publisher Name: Humana Press
Print ISBN: 978-1-58829-970-3
Online ISBN: 978-1-59745-394-3
eBook Packages: Springer Protocols